Loading data for GOSS — first visit, this takes a few seconds.
Gossamer Bio Inc. (GOSS)
: GOSS
· Precio en tiempo real · USD
n/a
n/a (n/a)
Al cierre: Invalid Date
Gossamer Bio Inc. (GOSS) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | n/a |
| Capitalización de mercado | n/a |
| Ingresos (TTM) | 53.29M |
| Beneficio neto (TTM) | -125.22M |
| Beta | n/a |
| EPS (TTM) | n/a |
| Ratio PER (TTM) | n/a |
| Adelante PE | -0.86 |
| P/B (TTM) | -0.23 |
| P/S (TTM) | 1.43 |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | NaN |
| Volumen medio (20D) | n/a |
| Abierto | n/a |
| Anterior Cerrar | n/a |
| Rango del día | n/a - n/a |
| Rango de 52 semanas | n/a - n/a |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It ha...
Industria Biotechnology
Sector Healthcare
IPO Fecha Feb 8, 2019
Empleados 161
Bolsa de Valores NasdaqGS
Símbolo bursátil GOSS
Sitio web https://www.gossamerbio.com
Desempeño financiero
En 2025, los ingresos de Gossamer Bio fueron 48.47M, una disminución de -57.74% en comparación con 114.7M del año anterior. Las ganancias fueron -170.37M, un aumento de 201.39%.
Estados financieros